Lo Ruby C, Fokkema Margriet T M, Curran Thomas, Darling Jeremy, Hamdan Allen D, Wyers Mark, Martin Michelle, Schermerhorn Marc L
Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.
Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.
J Vasc Surg. 2015 Feb;61(2):405-12. doi: 10.1016/j.jvs.2014.07.099. Epub 2014 Sep 18.
We sought to elucidate the risks for access site-related complications (ASCs) after percutaneous lower extremity revascularization and to evaluate the benefit of routine ultrasound-guided access (RUS) in decreasing ASCs.
We reviewed all consecutive percutaneous revascularizations (percutaneous transluminal angioplasty or stent) performed for lower extremity atherosclerosis at our institution from 2002 to 2012. RUS began in September 2007. Primary outcome was any ASC (bleeding, groin or retroperitoneal hematoma, vessel rupture, or thrombosis). Multivariable logistic regression was used to determine predictors of ASC.
A total of 1371 punctures were performed on 877 patients (43% women; median age, 69 [interquartile range, 60-78] years) for claudication (29%), critical limb ischemia (59%), or bypass graft stenosis (12%) with 4F to 8F sheaths. There were 72 ASCs (5%): 52 instances of bleeding or groin hematoma, nine pseudoaneurysms, eight retroperitoneal hematomas, two artery lacerations, and one thrombosis. ASCs were less frequent when RUS was used (4% vs 7%; P = .02). Multivariable predictors of ASC were age >75 years (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.1-3.7; P = .03), congestive heart failure (OR, 1.9; 95% CI, 1.1-1.3; P = .02), preoperative warfarin use (OR, 2.0; 95% CI, 1.1-3.5; P = .02), and RUS (OR, 0.4; 95% CI, 0.2-0.7; P < .01). Vascular closure devices (VCDs) were not associated with lower rates of ASCs (OR, 1.1; 95% CI, 0.6-1.9; P = .79). RUS lowered ASCs in those >75 years (5% vs 12%; P < .01) but not in those taking warfarin preoperatively (10% vs 13%; P = .47). RUS did not decrease VCD failure (6% vs 4%; P = .79).
We were able to decrease the rate of ASCs during lower extremity revascularization with the implementation of RUS. VCDs did not affect ASCs. Particular care should be taken with patients >75 years old, those with congestive heart failure, and those taking warfarin.
我们试图阐明经皮下肢血管重建术后与穿刺部位相关并发症(ASC)的风险,并评估常规超声引导穿刺(RUS)在降低ASC方面的益处。
我们回顾了2002年至2012年在本机构为下肢动脉粥样硬化进行的所有连续性经皮血管重建术(经皮腔内血管成形术或支架置入术)。RUS于2007年9月开始应用。主要结局是任何ASC(出血、腹股沟或腹膜后血肿、血管破裂或血栓形成)。采用多变量逻辑回归分析确定ASC的预测因素。
共对877例患者(43%为女性;中位年龄69岁[四分位间距,60 - 78岁])进行了1371次穿刺,用于治疗跛行(29%)、严重肢体缺血(59%)或旁路移植血管狭窄(12%),使用4F至8F鞘管。发生72例ASC(5%):52例出血或腹股沟血肿、9例假性动脉瘤、8例腹膜后血肿、2例动脉撕裂伤和1例血栓形成。使用RUS时ASC发生率较低(4%对7%;P = 0.02)。ASC的多变量预测因素为年龄>75岁(比值比[OR],2.0;95%置信区间[CI],1.1 - 3.7;P = 0.03)、充血性心力衰竭(OR,1.9;95% CI,1.1 - 1.3;P = 0.02)、术前使用华法林(OR,2.0;95% CI,1.1 - 3.5;P = 0.02)和RUS(OR,0.4;95% CI,0.2 - 0.7;P < 0.01)。血管闭合装置(VCD)与较低的ASC发生率无关(OR,1.1;95% CI,0.6 - 1.9;P = 0.79)。RUS降低了年龄>75岁患者的ASC发生率(5%对12%;P < 0.01),但未降低术前使用华法林患者的ASC发生率(10%对13%;P = 0.47)。RUS未降低VCD失败率(6%对4%;P = 0.79)。
通过实施RUS,我们能够降低下肢血管重建术中ASC的发生率。VCD不影响ASC的发生。对于年龄>75岁、患有充血性心力衰竭以及使用华法林的患者应格外小心。